Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma.

Kraan W, van Keimpema M, Horlings HM, Schilder-Tol EJ, Oud ME, Noorduyn LA, Kluin PM, Kersten MJ, Spaargaren M, Pals ST.

Leukemia. 2014 Mar;28(3):719-20. doi: 10.1038/leu.2013.348. Epub 2013 Nov 20. No abstract available.

PMID:
24253023
2.

CD79B and MYD88 mutations in diffuse large B-cell lymphoma.

Kim Y, Ju H, Kim DH, Yoo HY, Kim SJ, Kim WS, Ko YH.

Hum Pathol. 2014 Mar;45(3):556-64. doi: 10.1016/j.humpath.2013.10.023. Epub 2013 Oct 31.

PMID:
24444466
3.

Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations.

Yamada S, Ishida Y, Matsuno A, Yamazaki K.

Leuk Lymphoma. 2015 Jul;56(7):2141-5. doi: 10.3109/10428194.2014.979413. Epub 2015 Jan 14.

PMID:
25347427
4.

Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations.

Kersten MJ, Kraan W, Doorduijn J, Bromberg J, Lam K, Kluin PM, van der Holt BJ, Spaargaren M, Pals ST.

Blood Cancer J. 2014 Dec 12;4:e266. doi: 10.1038/bcj.2014.87. No abstract available.

5.

Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma.

Taniguchi K, Takata K, Chuang SS, Miyata-Takata T, Sato Y, Satou A, Hashimoto Y, Tamura M, Nagakita K, Ohnishi N, Noujima-Harada M, Tabata T, Kikuti YY, Maeda Y, Nakamura N, Tanimoto M, Yoshino T.

Am J Surg Pathol. 2016 Mar;40(3):324-34. doi: 10.1097/PAS.0000000000000592.

PMID:
26752547
6.

Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas.

Nakamura T, Tateishi K, Niwa T, Matsushita Y, Tamura K, Kinoshita M, Tanaka K, Fukushima S, Takami H, Arita H, Kubo A, Shuto T, Ohno M, Miyakita Y, Kocialkowski S, Sasayama T, Hashimoto N, Maehara T, Shibui S, Ushijima T, Kawahara N, Narita Y, Ichimura K.

Neuropathol Appl Neurobiol. 2016 Apr;42(3):279-90. doi: 10.1111/nan.12259. Epub 2015 Jul 20.

PMID:
26111727
7.

High prevalence of the MYD88 mutation in testicular lymphoma: Immunohistochemical and genetic analyses.

Oishi N, Kondo T, Nakazawa T, Mochizuki K, Tanioka F, Oyama T, Yamamoto T, Iizuka J, Tanabe K, Shibata N, Kirito K, Katoh R.

Pathol Int. 2015 Oct;65(10):528-35. doi: 10.1111/pin.12336. Epub 2015 Aug 4.

PMID:
26388135
8.

Prevalence of targetable oncogenic mutations and genomic alterations in Epstein-Barr virus-associated diffuse large B-cell lymphoma of the elderly.

Gebauer N, Gebauer J, Hardel TT, Bernard V, Biersack H, Lehnert H, Rades D, Feller AC, Thorns C.

Leuk Lymphoma. 2015 Apr;56(4):1100-6. doi: 10.3109/10428194.2014.944522. Epub 2014 Aug 21.

PMID:
25030036
9.

Absence of CXCR4 mutations but high incidence of double mutant in CD79A/B and MYD88 in primary central nervous system lymphoma.

Poulain S, Boyle EM, Tricot S, Demarquette H, Doye E, Roumier C, Duthilleul P, Preudhomme C, Maurage CA, Morschhauser F.

Br J Haematol. 2015 Jul;170(2):285-7. doi: 10.1111/bjh.13293. Epub 2015 Feb 2. No abstract available.

PMID:
25643939
10.

Multiplex sequencing for EZH2, CD79B, and MYD88 mutations using archival cytospin preparations from B-cell non-Hodgkin lymphoma aspirates previously tested for MYC rearrangement and IGH/BCL2 translocation.

Santos Gda C, Saieg MA, Ko HM, Geddie WR, Boerner SL, Craddock KJ, Crump M, Bailey D.

Cancer Cytopathol. 2015 Jul;123(7):413-20. doi: 10.1002/cncy.21535. Epub 2015 Mar 23.

11.

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.

Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih CJ, Williams PM, Shaffer AL, Gerecitano J, de Vos S, Goy A, Kenkre VP, Barr PM, Blum KA, Shustov A, Advani R, Fowler NH, Vose JM, Elstrom RL, Habermann TM, Barrientos JC, McGreivy J, Fardis M, Chang BY, Clow F, Munneke B, Moussa D, Beaupre DM, Staudt LM.

Nat Med. 2015 Aug;21(8):922-6. doi: 10.1038/nm.3884. Epub 2015 Jul 20.

PMID:
26193343
12.

VR09 cell line: an EBV-positive lymphoblastoid cell line with in vivo characteristics of diffuse large B cell lymphoma of activated B-cell type.

Nichele I, Zamò A, Bertolaso A, Bifari F, Tinelli M, Franchini M, Stradoni R, Aprili F, Pizzolo G, Krampera M.

PLoS One. 2012;7(12):e52811. doi: 10.1371/journal.pone.0052811. Epub 2012 Dec 21.

13.

Acquisition of MYD88 L265P mutation during treatment of diffuse large B cell lymphoma of the parotid gland.

Fujiishi K, Kitazawa R, Nagai Y, Watanabe T, Bando K, Kobayashi S, Yakushijin Y, Haraguchi R, Kitazawa S.

Virchows Arch. 2014 Jan;464(1):121-4. doi: 10.1007/s00428-013-1514-1. Epub 2013 Nov 22. No abstract available.

PMID:
24259032
14.

Oncogenic MYD88 mutation drives Toll pathway to lymphoma.

Jeelall YS, Horikawa K.

Immunol Cell Biol. 2011 Aug;89(6):659-60. doi: 10.1038/icb.2011.31. Epub 2011 Apr 26. No abstract available.

PMID:
21519346
15.

Oncogenically active MYD88 mutations in human lymphoma.

Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, Kohlhammer H, Xu W, Yang Y, Zhao H, Shaffer AL, Romesser P, Wright G, Powell J, Rosenwald A, Muller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Staudt LM.

Nature. 2011 Feb 3;470(7332):115-9. doi: 10.1038/nature09671. Epub 2010 Dec 22.

16.

MYD88 somatic mutation is a genetic feature of primary cutaneous diffuse large B-cell lymphoma, leg type.

Pham-Ledard A, Cappellen D, Martinez F, Vergier B, Beylot-Barry M, Merlio JP.

J Invest Dermatol. 2012 Aug;132(8):2118-20. doi: 10.1038/jid.2012.102. Epub 2012 Apr 12. No abstract available.

17.

MYD88 expression and L265P mutation in diffuse large B-cell lymphoma.

Choi JW, Kim Y, Lee JH, Kim YS.

Hum Pathol. 2013 Jul;44(7):1375-81. doi: 10.1016/j.humpath.2012.10.026. Epub 2013 Feb 4.

PMID:
23380077
18.

High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type.

Pham-Ledard A, Beylot-Barry M, Barbe C, Leduc M, Petrella T, Vergier B, Martinez F, Cappellen D, Merlio JP, Grange F.

JAMA Dermatol. 2014 Nov;150(11):1173-9. doi: 10.1001/jamadermatol.2014.821.

PMID:
25055137
19.

MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma.

Fernández-Rodríguez C, Bellosillo B, García-García M, Sánchez-González B, Gimeno E, Vela MC, Serrano S, Besses C, Salar A.

Leukemia. 2014 Oct;28(10):2104-6. doi: 10.1038/leu.2014.184. Epub 2014 Jun 6. No abstract available.

PMID:
24903481
20.

Allele-specific PCR is a powerful tool for the detection of the MYD88 L265P mutation in diffuse large B cell lymphoma and decalcified bone marrow samples.

Staiger AM, Ott MM, Parmentier S, Rosenwald A, Ott G, Horn H, Griese EU.

Br J Haematol. 2015 Oct;171(1):145-8. doi: 10.1111/bjh.13369. Epub 2015 Mar 30. No abstract available.

PMID:
25816840

Supplemental Content

Support Center